KLK7 (Kallikrein Related Peptidase 7)

Novel agents, including luspatercept, matriptase-2 inhibitors, and anti-hemojuvelin antibodies, represent promising interventions for conditions characterized by ineffective erythropoiesis and iron maldistribution...Critical evaluation of clinical trial evidence reveals both therapeutic promise and implementation challenges, highlighting the need for continued mechanistic research and translational development. Future directions emphasize combination therapeutic strategies, biomarker-driven patient stratification, and the development of targeted interventions addressing the complex interplay between iron metabolism, inflammation, and hematopoietic function.

Additionally, KLK7 overexpression altered cell morphology, upregulated moesin (MSN) and integrin subunits, suggesting cytoskeletal remodeling and matrix interactions. Taken together, these findings suggest that KLK7 is a driver of CRC progression and could serve as a potential prognostic marker for aggressive forms of CRC.

The protein-ligand combination was stable during the MD simulation. Post simulation analysis, such as RMSF (Root Mean Square Deviation), RMSD (Root Mean Square Deviation), Rg (Radius of Gyration), and HB (Hydrogen Bonding), revealed the stability of the proposed compound with the KLK7 protein.

This study underscores the critical roles of serine proteases KLK5, KLK7, and KLK14 in cervical carcinogenesis, suggesting that these serine proteases are promising targets for the development of novel therapeutic strategies in cervical cancer.

Objective To investigate the effect of the small molecule inhibitor C42 of kallikrein-related peptidase 7(KLK7)on ovarian cancer with elevated expression of KLK7 and evaluate the feasibility of C42 as a new therapeutic strategy for ovarian cancer.Methods The CCK-8 assay,flow cytometry,cell scratch assay,Transwell assay,and Western blotting were employed to assess the effects of C42 on the proliferation,migration,and invasion of the ovarian cancer cell line SKOV3,which was characterized by high KLK7 expression.Additionally,a subcutaneous xenograft model of ovarian cancer was established with SKOV3 cells in nude mice to evaluate the effects of C42 on the tumor growth and metastasis.The expression levels of proteins associated with tumor metastasis and invasion in the tumor tissue were examined by immunohistochemical techniques.Results The cellular experiment showed that C42 suppressed the proliferation,migration,and invasion(all P<0.001)of SKOV3 cells,compared with the control group.The animal experiment showed that compared with the control group,the 10.2 mg/kg C42 group exhibited a decreased tumor weight(P=0.009) and attenuated liver metastases.Immunohistochemical staining revealed that the 10.2 mg/kg C42 group demonstrated down-regulated expression of the tumor proliferation marker Ki-67(P=0.002)and the tumor metastasis and invasion-associated proteins such as matrix metalloproteinase-9(P=0.027)and Vimentin(P=0.039).Conclusion The small molecule inhibitor C42 of KLK7 effectively suppresses the proliferation,migration,and invasion of ovarian cancer SKOV3 cells.

In addition, the developed KLK7 immunosensor (KLK7-Ab@PLGA-NSGQDsCS) demonstrated excellent performance in the analysis of spiked samples, achieving an average recovery rate of 97.52%. This study highlights a highly sensitive immunosensor, offering potential for early cancer detection, with promising avenues for broader biomarker applications in clinical diagnostics.

This study identified gene expression signatures associated with breast cancer risk and molecular subtypes. These findings provide insights into the biological processes that may drive breast cancer progression and could inform the development of prognostic biomarkers and personalized therapeutic strategies.

Adverse factors, including KLK7, have a decreasing impact on survival over time. Conditional survival analysis based on KLK7 can provide more accurate survival predictions for patients who has identified KLK7.

KLK7 could be essential in the cancerous advancement of PTC by influencing the EMT via the MAPK/ERK signaling pathway, thereby impacting the growth, migration, and invasiveness of PTC cells. KLK7 appears to be a promising candidate for targeting in PTC therapy.

Of the 978 patients (Caucasians:81.7%; African Americans:2.58%; other races: 5.7%), the risk or genetic profile was as follows: MP: Ultra-Low = 76 (8%), Low = 176 (18%), High1 = 315 (32%), and High-2 = 411 (42%); BP: Luminal A 250 (26%), Luminal B = 250 (26%), HER2 = 228 (23%), and Basal = 250 (26%). The mean age was 58.84±13.04, the average BMI was 30.04±7.34, and the majority were postmenopausal (n = 717, 73%). The first five PCs accounted for 63.11% of the total variance of the dataset.

KLK1, KLK6, KLK7, KLK13, and KLK14 have potential as diagnostic and prognostic biomarkers, among which KLK1 is the most significant. This study may provide detailed immune information and promising targets for KIRC immunotherapy to assist in designing new immunotherapies.

These data provide a comprehensive overview on KLK7 expression in normal and neoplastic human tissues. The prognostic relevance of KLK7 expression and the possible role of KLK7 as a drug target need to be further investigated.